Navigation Links
Compumedics Home Sleep Testing System Selected for Use in US National Institute of Health (NIH)-Sponsored Multi-Ethnic Study of Atherosclerosis (MESA) Sleep Study

CHARLOTTE, N.C., Dec. 6, 2010 /PRNewswire/ -- Compumedics USA, Inc. (CMP.ASX) today announced its new Somte® PSG portable sleep-testing systems were chosen as part of a major new study to further investigate the link between sleep disorders and cardio-vascular disease in various ethnic and racial populations.  Somte® PSG was chosen because of its ability to record complex sleep studies in the home environment with acceptable participant burden, according to Dr. Susan Redline, Professor of Medicine at Harvard Medical School and the senior investigator for the Multi-Ethnic Study of Atherosclerosis (MESA) Sleep Study.

The contract is worth approximately US $300 thousand and continues a long record of success for Compumedics in supplying NIH-funded studies.  Importantly it supports Compumedics' technology and product offering for the relatively new home sleep study (HST) market, which is undergoing double digit growth with global HST revenues already exceeding US $20 million.  Patients enrolled in the MESA Sleep Study will be monitored from the Reading Center located at Brigham and Women's Hospital in Boston, Mass.

"The Compumedics Somte® PSG systems allow us to record all of the parameters of sleep and breathing that we need to evaluate and quantify abnormal sleep patterns but in the more natural environment of the patients' homes," said Prof. Susan Redline, M.D., M.P.H.  "The Somte® PSG systems also have the ability to capture and analyze heart rhythm data related to the sleep and breathing patterns, which is very important in studying this population."

Dr. David Burton, chairman and chief executive officer of Compumedics noted, "The NIH MESA Sleep Study holds special significance to Compumedics.  It was Professor Redline's team who led the original Sleep Heart Health Study (SHHS), during their important investigation into the cardio-vascular consequences of sleep-disordered breathing.  It is once again an honor to be working with Prof. Redline and her team.  Somte® PSG systems uniquely deliver uncompromised data recording with integrated waveform displays, but at the same time incorporate the user friendliness and trouble-free patient operation essential for reliable home sleep testing.  These factors will enable Prof. Redline's team to collect high quality and meaningful data from these patients with a minimum of inconvenience. In addition, this project comes at an opportune time for Compumedics when the company is focusing its growth on its core product lines, including Somte® PSG, with the expansion of its global sales force."  

The MESA was established by the NIH in 2000 with the aims of identifying ethnic and racial differences in risk factors and subclinical and clinical cardiovascular disease. This new MESA Sleep Study has been funded to further understand these risks.

Over the last 15 years, Compumedics has been selected to supply sleep recorders for several NIH-funded studies, including the multi-center SHHS involving more than 6000 subjects. The Somte® PSG System incorporates advanced technology to record sleep studies in either the home or the sleep-lab settings.

Jeff Kuznia, Compumedics USA's vice-president of sales and marketing, said, "Compumedics' products successfully met the demanding specifications required to undertake this study and coupled with the unique expertise of the MESA research team, we will improve our understanding of the impact of sleep disorders on cardiovascular disease across a broad ethnic and racial mix of the US population.  This project is timely as we are in the process of expanding our US sales force and releasing our new range of Long Term Monitoring (LTM) EEG and HST products."

About Compumedics

Compumedics Limited, was founded in 1987 by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerized sleep laboratory.  Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, with over 8,000 participants scheduled by 2008.   With headquarters in Melbourne, Australia and offices in the United States and Europe, its products are distributed in over 50 countries. In 1998 Compumedics was awarded the overall Australian Exporter of the Year. In 2000 Compumedics was listed on the Australian Stock Exchange. In 2002, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain research.  In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products.  In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In 2004, Compumedics acquired Germany-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In 2006, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somte® recorder product. In 2007, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In 2008 the DWL division received a top 100 German Innovation award.  With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from $9 million (1999) to $39 million (2008). In 2009 Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In 2010 Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its world leading devices for sleep diagnostics.  

For further background please visit:

For further information please contact:

Russo Partners: Robert E. Flamm, Ph.D.; 212-845-4226; ;  or Tony Russo, Ph.D., 212-845-4251;

Compumedics USA S&M VP: Mr. Jeffrey Kuznia 704-749-3204;

Compumedics CEO/Chairman: Dr. David Burton 61-3-8420-7300;

Investors: CMP.ASX (ASX.COM)

SOURCE Compumedics USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Global Sleeping Pills Industry
2. Sleep Solutions, Inc. Re-incorporates as NovaSom, Inc.
3. Three Leading Sleep Solution Providers Choose Watermark Medicals Web-Enabled Home Sleep Testing Solutions
4. Graymark Healthcare Agrees to Sell Pharmacy Division to Walgreens Creating Pure Play Sleep Apnea Company
5. VirtuOx and Watermark Medical Announce Strategic Alliance to Expand Sleep Apnea Home Sleep Testing Solutions
6. New Study Shows ENJUVIA® Significantly Reduced Sleep Time Awakenings Caused by Hot Flashes in Postmenopausal Women
7. Implanted Sleep Device Shows Promising Early Results
8. Daylight Savings Time - Turn the Clocks Ahead Without MISSING an Hour of Sleep
9. Local Head-Injury Patients Sought for Study Investigating Potential Treatment for Daytime Sleepiness
10. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
11. Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... --> --> Opportunities ... and PPAR Agonists cholesterol-lowering drugs market ? ... rates? This visiongain report shows you potential ... there. ,  ,Our 199-page report provides 153 tables, charts, ... industry and the future market prospects. Our new study ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... it comes to several aspects of orthopedic care. They have received recognition for ... and general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to ... it is critical that the first impression be positive and reflects business values. If ... to buy anything or want to return. They will also share their thoughts about ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... States to support their local poison centers through donations on Tuesday, Dec. 1, ... calls it “a day that inspires people to collaborate in improving their local ...
Breaking Medicine News(10 mins):